Jyong Biotech (MENS) Fundamental Analysis: Revenue, Earnings & Valuation

2.84 / 10

Underperform

Fundamental rating is Underperform with a 2.8/10 quality score. Strengths include a solid current‑liabilities‑to‑total‑liabilities ratio (45.8%) and healthy interest coverage (27.7%). Weaknesses stem from high long‑term‑debt‑to‑working‑capital (7.35%) and elevated cost‑of‑sales (73%).

Analysis Checks(6/7)

Total operating revenue (YoY growth rate %)

Value292.23

Score2/3

Weight-3.94%

1M Return0.13%

Inventory turnover ratio

Value37.77

Score2/3

Weight32.69%

1M Return-1.18%

Current liabilities / Total liabilities (%)

Value45.81

Score2/3

Weight-11.08%

1M Return0.36%

Long-term debt to working capital ratio (%)

Value7.35

Score1/3

Weight19.27%

1M Return-0.65%

Interest coverage ratio (EBIT / Interest expense) (%)

Value27.69

Score2/3

Weight33.24%

1M Return-1.17%

Operating revenue (YoY growth rate %)

Value389.68

Score2/3

Weight-1.59%

1M Return0.05%

Cost of sales ratio (%)

Value73.08

Score2/3

Weight31.42%

1M Return-1.13%

Is MENS fundamentally strong?

MENS scores 2.84/10 on fundamentals and holds a Premium valuation at present. Backed by its 0.00% ROE, 0.00% net margin, 0.00 P/E ratio, -8.29 P/B ratio, and 0.00% earnings growth, these metrics solidify its Underperform investment rating.